Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention



Kwon, Soonil, Jung, Jin Hyung, Choi, Eue Keun, Lee, Seung Woo, Park, Jiesuck, Lee, So Ryoung, Kang, Jeehoon, Han, Kyungdo, Park, Kyung Woo, Oh, Seil
et al (show 1 more authors) (2021) Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. KOREAN CIRCULATION JOURNAL, 51 (5). pp. 409-422.

Access the full-text of this item by clicking on the Open Access link.
[img] Text
Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibr.pdf - Published version

Download (2MB) | Preview

Abstract

<h4>Background and objectives</h4>Antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) has changed in recent years with new data from large randomized trials and updates to clinical guidelines. This study aimed to investigate the trends in periprocedural antithrombotic regimens in Korean patients with AF undergoing PCI with non-vitamin K antagonist oral anticoagulants (NOACs).<h4>Methods</h4>Using the claims database of the Health Insurance Review and Assessment during 2013-2018, 27,594 patients with AF undergoing PCI were identified. The annual prevalence of PCI and prescriptions of each antithrombotic agent, including antiplatelet agents and oral anticoagulants, within 30 days after PCI were investigated.<h4>Results</h4>During 2013-2018, the number of patients with AF undergoing PCI increased up to 1.3-fold (from 3,913 to 5,075 patients per year). After the introduction of NOACs, the proportion of dual antiplatelet therapy (DAPT) decreased from 71.9% to 49.8% but still occupied the largest proportion among antithrombotic regimens. Triple antithrombotic therapy (TAT) use increased from 25.4% to 46.0%, and NOAC has rapidly replaced warfarin as the oral anticoagulant of choice. TAT was preferred to DAPT for patients with CHA₂DS₂-VASc score ≥2. Among various factors, prior intracranial hemorrhage was the most powerful predictor of favoring DAPT use over TAT.<h4>Conclusion</h4>Since the introduction of NOACs, the patterns of periprocedural antithrombotic regimens have changed rapidly toward more use of TAT, specifically with NOAC-based regimen. Appropriate stroke prevention with oral anticoagulants is still underutilized in patients with AF undergoing PCI in Korea.

Item Type: Article
Uncontrolled Keywords: Atrial fibrillation, Percutaneous coronary intervention, Antiplatelet drugs, Anticoagulant drugs
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 30 Jun 2021 14:44
Last Modified: 18 Jan 2023 21:37
DOI: 10.4070/kcj.2020.0407
Open Access URL: https://e-kcj.org/DOIx.php?id=10.4070/kcj.2020.040...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3128302